Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.

ABSTRACT:

Background

Existing treatments for metastatic breast cancer (mBC) are often effective but can cause adverse events (AEs). This study aimed to identify AEs associated with chemotherapies commonly used in mBC treatment (phase 1) and to quantify the economic impact of these AEs (phase 2).

Materials and methods

Patients in phase 1 had at least one claim for therapy for mBC, with at least one episode with single or multiple agents. The most common chemotherapy-related complications were identified using medical and pharmacy claims data. In phase 2, patients meeting study criteria were divided into four treatment cohorts by the line of treatment and chemotherapy received: first-line taxane-treated patients, second-line taxane-treated patients, first-line capecitabine-treated patie

SUBMITTER: Hurvitz S 

PROVIDER: S-EPMC4153460 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature